English
Skyline Medical Inc.
EDGAR113 filing records in this dataset, filed from 2009-11-25 to 2026-08-14. Reported financial figures are available; chart coverage varies by period.
- Cash and cash equivalents
- 21.9 million USD Source
Exact value
21900000 USD
- Long-term debt including current maturities
- 0 USD Source
Exact value
0 USD
- Shares outstanding
- 11.4 million shares Source
Exact value
11384940 shares
Reported share-count change
18.63% · 1.79 million shares
Year-over-year change in reported shares. Splits, issuance and buybacks can affect this figure; it does not isolate employee compensation or economic dilution.
Includes later revisions to earlier periods. Annual charts exclude incomplete years.
Latest filing recorded: 2026-08-14.
Financial data available through: 2025-12-31.
Coverage by financial measure
- revenue: No compatible figures in this window
- Operating income: 6 of 11 periods available· newest 2025-12-31
- Net income: 6 of 11 periods available· newest 2025-12-31
- Operating cash flow: 7 of 11 periods available· newest 2025-12-31
- Capital expenditure: 7 of 11 periods available· newest 2025-12-31
- Total assets: 7 of 11 periods available· newest 2025-12-31
- Total liabilities: 7 of 11 periods available· newest 2025-12-31
- Current assets: 7 of 11 periods available· newest 2025-12-31
- Current liabilities: 7 of 11 periods available· newest 2025-12-31
- Cash and cash equivalents: 7 of 11 periods available· newest 2025-12-31
- Long-term debt including current maturities: 1 of 11 periods available· newest 2021-12-31
- Shares outstanding: 7 of 11 periods available· newest 2025-12-31
Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.
What changed year over year
Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.
Net income
−USD 220.43 millionPrior period
−USD 12.66 million
–
Current period
−USD 233.1 million
–
Exact inputs and evidence
-233095203 − -12664388 = -220430815 USD
-12664388 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-233095203 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+USD 227,045Prior period
−USD 10.1 million
–
Current period
−USD 9.88 million
–
Exact inputs and evidence
-9876039 − -10103084 = 227045 USD
-10103084 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-9876039 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-100%Prior period
USD 9,510
–
Current period
USD 0
–
Exact inputs and evidence
-0 − 9510 = -9510 USD
9510 USD · 2024-01-01 – 2024-12-31
Inspect prior input Prior source-0 USD · 2025-01-01 – 2025-12-31
Inspect current input Current sourceShare or cite
The citation records this snapshot. The page link may show a newer release later.
Comparable inputs unavailable for: Revenue.
Where revenue goes
How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.
Revenue is not reported for this company, so its costs cannot be shown as a share of it.
Growth
Sales over time and how quickly they are changing.
Revenue
Revenue reported for each complete financial period.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Revenue growth
Change in revenue from the same financial period one year earlier.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Profit and cash
How much revenue becomes profit, and how much cash operations generate.
Profit margins
Operating income, net income and free cash flow as a share of revenue.
- Operating margin
- Net margin
- Free cash flow margin
Values and sources
| Period | Series | Value | Source evidence |
|---|
Operating cash flow
Cash generated by the company’s normal business operations.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Free cash flow
Operating cash flow minus capital expenditure for the same period and unit.
Values and sources
| Period | Series | Value(USD) | Source evidence |
|---|
Balance sheet
Liabilities and short-term ability to meet obligations at each period end.
Liabilities to assets
Total liabilities as a share of total assets.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Current assets to current liabilities
Current assets divided by current liabilities.
Values and sources
| Period | Series | Value | Source evidence |
|---|
Cash generation
Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.
| Period | Net income | Operating cash flow | Capital expenditure | Free cash flow |
|---|---|---|---|---|
| 2015 2015-01-01 – 2015-12-31 | Unavailable Not reported for this period. | −USD 7.49 million Exact valueExact value: -7487293 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 32,470 Exact valueExact value: 32470 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 7.52 million Calculation and evidence-7487293 − 32470 USD Exact free cash flow: -7519763 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2020 2020-01-01 – 2020-12-31 | −USD 25.88 million Exact valueExact value: -25884397 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 12.26 million Exact valueExact value: -12257732 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 298,379 Exact valueExact value: 298379 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 12.56 million Calculation and evidence-12257732 − 298379 USD Exact free cash flow: -12556111 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2021 2021-01-01 – 2021-12-31 | −USD 19.66 million Exact valueExact value: -19657174 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 12.21 million Exact valueExact value: -12208929 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 910,429 Exact valueExact value: 910429 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 13.12 million Calculation and evidence-12208929 − 910429 USD Exact free cash flow: -13119358 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2022 2022-01-01 – 2022-12-31 | −USD 25.74 million Exact valueExact value: -25737634 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 12.37 million Exact valueExact value: -12370800 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 419,869 Exact valueExact value: 419869 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 12.79 million Calculation and evidence-12370800 − 419869 USD Exact free cash flow: -12790669 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2023 2023-01-01 – 2023-12-31 | −USD 13.98 million Exact valueExact value: -13983967 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 11.78 million Exact valueExact value: -11784070 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 21,533 Exact valueExact value: 21533 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 11.81 million Calculation and evidence-11784070 − 21533 USD Exact free cash flow: -11805603 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2024 2024-01-01 – 2024-12-31 | −USD 12.66 million Exact valueExact value: -12664388 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.1 million Exact valueExact value: -10103084 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 9,510 Exact valueExact value: 9510 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 10.11 million Calculation and evidence-10103084 − 9510 USD Exact free cash flow: -10112594 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
| 2025 2025-01-01 – 2025-12-31 | −USD 233.1 million Exact valueExact value: -233095203 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 9.88 million Exact valueExact value: -9876039 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | USD 0 Exact valueExact value: -0 USD Share or citeThe citation records this snapshot. The page link may show a newer release later. | −USD 9.88 million Calculation and evidence-9876039 − -0 USD Exact free cash flow: -9876039 USD
Share or citeThe citation records this snapshot. The page link may show a newer release later. |
Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.
Dataset coverage and company identifiers
Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.
113 filings · 3,852 latest values · 3,852 originally reported values
Dataset published . Source filing dates and reporting periods are shown separately.
Identifiers: 0001446159, 1446159, AGPU, POAI, SKLN, SKLND, aipt, bior, edgar:1446159, poai, skln
Also known as Axe Compute Inc, Axe Compute Inc., BioDrain Medical, Inc., Precision Therapeutics Inc., Predictive Oncology Inc., Skyline Medical Inc.